A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence

Research output: Contribution to journalDebate/Note/Editorial


While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.


  • Mark W. Kieran
  • Hubert Caron
  • Jeanette Falck Winther
  • Tara O. Henderson
  • Riccardo Haupt
  • Lars Hjorth
  • Melissa M. Hudson
  • Leontien C.M. Kremer
  • Helena J. van der Pal
  • Andrew D.J. Pearson
  • Leonardo Pereira
  • Gregory Reaman
  • Roderick Skinner
  • Gilles Vassal
  • Susan L. Weiner
  • Danielle Horton Taylor
  • ACCELERATE Long-Term Follow-Up Working Group
External organisations
  • F. Hoffmann-La Roche AG
  • Danish Cancer Society Research Center
  • Aarhus University Hospital
  • University of Chicago
  • Gaslini Children's Hospital
  • Skåne University Hospital
  • St Jude Children´s Research Hospital, Memphis
  • United States Food and Drug Administration
  • Bristol-Myers Squibb
  • PanCare, The Netherlands
  • Princess Maxima Center for Pediatric Oncology/Hematology
  • Wilhelmina Children’s Hospital
  • University of Newcastle upon Tyne
  • Institut Gustave Roussy
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Childhood cancer, Immunotherapy, Long-term follow-up, Long-term survivor, Pediatric cancer, survivorship, Targeted therapy
Original languageEnglish
Article numbere29047
JournalPediatric Blood and Cancer
Publication statusE-pub ahead of print - 2021
Publication categoryResearch